Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17982184 | 0.83 | NOTUM (0.43) | KDM4ENOTUMTDP1KMT2AMEN1 | |
| SCHEMBL4314431 | 0.83 | KDM4E (0.50) | KDM4ETDP1KMT2AMEN1MYC | |
| SCHEMBL951003 | 0.81 | KDM4E (0.48) | KDM4ENOTUMTDP1KMT2AMEN1 | |
| SCHEMBL27789247 | 0.81 | KDM4E (0.53) | KDM4ENOTUMTDP1KMT2AMEN1 | |
| SCHEMBL21481794 | 0.81 | GAA (0.50) | KDM4EALDH1A1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL25293621 | 0.79 | KDM4E (0.46) | KDM4ENOTUMTDP1KMT2AMEN1 | |
| SCHEMBL23682334 | 0.79 | KDM4E (0.46) | KDM4ETDP1KMT2AMEN1MYC | |
| SCHEMBL27281805 | 0.78 | KDM4E (0.48) | KDM4ENOTUMTDP1KMT2AMEN1 | |
| SCHEMBL23556673 | 0.77 | DHODH (0.42) | KDM4ENOTUMKMT2AKEAP1AKR1C2 | |
| SCHEMBL10953308 | 0.76 | TPMT (0.46) | KDM4ENOTUMTDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3781550-B1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-2358706-A1 | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto | Portola Pharmaceuticals, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010054020-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2076510-A2 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, IN DIFFERENT CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND FORMULATIONS THEREOF, FOR THE TREATMENT OF THROMBOSIS AND TROMBOSIS RELATED CONDITIONS | Portola Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1951254-A4 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARM INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042916-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008137809-A2 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL] -5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, IN DIFFERENT CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1951254-A2 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | Portola Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007056219-A2 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | KDM4E 719/4885NOTUM 1291/4885TDP1 4465/4885 |
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | KDM4E 2311/4885NOTUM 3679/4885TDP1 826/4885 |
| US-20090042916-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | KDM4E 2311/4885NOTUM 3679/4885TDP1 826/4885 |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | KDM4E 719/4885NOTUM 1291/4885TDP1 4465/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | KDM4E 719/4885NOTUM 1291/4885TDP1 4465/4885 |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | P2RX7, P2RY1, P2RY6 | KDM4E 3098/4885NOTUM 3885/4885TDP1 718/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | KDM4E 719/4885NOTUM 1291/4885TDP1 4465/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | KDM4E 719/4885NOTUM 1291/4885TDP1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.